DD202001A5 - Verfahren zur herstellung von aminoaethanolen - Google Patents

Verfahren zur herstellung von aminoaethanolen Download PDF

Info

Publication number: DD202001A5
Authority: DD; German Democratic Republic
Prior art keywords: compound; general formula; group; sup; carbon atoms
Prior art date: 1980-07-09

Application number

DD81231626A

Other languages

German (de)

English (en)

Inventor

Otto A T Ohlsson

Leif A Svensson

Leopold K I Wetterlin

Original Assignee

Draco Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1980-07-09

Filing date

1981-07-09

Publication date

1983-08-24

1981-07-09 Application filed by Draco Ab filed Critical Draco Ab

1983-08-24 Publication of DD202001A5 publication Critical patent/DD202001A5/de

Links

238000000034 method Methods 0.000 title claims abstract description 32
230000008569 process Effects 0.000 title claims abstract description 5
238000004519 manufacturing process Methods 0.000 title description 5
150000001875 compounds Chemical class 0.000 claims abstract description 135
238000002360 preparation method Methods 0.000 claims abstract description 23
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 20
125000000217 alkyl group Chemical group 0.000 claims abstract description 17
150000003839 salts Chemical class 0.000 claims abstract description 10
230000002829 reductive effect Effects 0.000 claims abstract description 4
125000003545 alkoxy group Chemical group 0.000 claims abstract description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 23
125000006239 protecting group Chemical group 0.000 claims description 14
239000007858 starting material Substances 0.000 claims description 13
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
229910014033 C-OH Inorganic materials 0.000 claims description 6
229910014570 C—OH Inorganic materials 0.000 claims description 6
UJPKMTDFFUTLGM-UHFFFAOYSA-N 1-aminoethanol Chemical class CC(N)O UJPKMTDFFUTLGM-UHFFFAOYSA-N 0.000 claims description 3
230000003287 optical effect Effects 0.000 claims description 3
125000005843 halogen group Chemical group 0.000 claims description 2
239000012948 isocyanate Substances 0.000 claims description 2
150000002513 isocyanates Chemical class 0.000 claims description 2
150000001412 amines Chemical class 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 19
239000000126 substance Substances 0.000 abstract description 18
230000009471 action Effects 0.000 abstract description 14
239000000543 intermediate Substances 0.000 abstract description 10
239000000825 pharmaceutical preparation Substances 0.000 abstract description 8
229910052739 hydrogen Inorganic materials 0.000 abstract description 4
229910052799 carbon Inorganic materials 0.000 abstract description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
230000001747 exhibiting effect Effects 0.000 abstract 1
238000012360 testing method Methods 0.000 description 71
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 70
XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 60
229960000195 terbutaline Drugs 0.000 description 59
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
239000000243 solution Substances 0.000 description 31
210000002966 serum Anatomy 0.000 description 28
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 27
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 25
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 20
239000000203 mixture Substances 0.000 description 16
239000000047 product Substances 0.000 description 15
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 13
239000004480 active ingredient Substances 0.000 description 11
239000000706 filtrate Substances 0.000 description 11
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 10
230000000572 bronchospasmolytic effect Effects 0.000 description 10
238000001704 evaporation Methods 0.000 description 10
241000282472 Canis lupus familiaris Species 0.000 description 9
230000008020 evaporation Effects 0.000 description 9
229920002261 Corn starch Polymers 0.000 description 8
108010010803 Gelatin Proteins 0.000 description 8
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
241001465754 Metazoa Species 0.000 description 8
239000008120 corn starch Substances 0.000 description 8
239000008273 gelatin Substances 0.000 description 8
229920000159 gelatin Polymers 0.000 description 8
235000019322 gelatine Nutrition 0.000 description 8
235000011852 gelatine desserts Nutrition 0.000 description 8
239000008101 lactose Substances 0.000 description 8
241000700198 Cavia Species 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
230000002057 chronotropic effect Effects 0.000 description 7
230000000297 inotrophic effect Effects 0.000 description 7
235000019359 magnesium stearate Nutrition 0.000 description 7
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
-1 aliphatic alcohols Chemical class 0.000 description 6
229940124630 bronchodilator Drugs 0.000 description 6
230000000747 cardiac effect Effects 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
239000003814 drug Substances 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
239000012071 phase Substances 0.000 description 6
230000003389 potentiating effect Effects 0.000 description 6
239000000454 talc Substances 0.000 description 6
235000012222 talc Nutrition 0.000 description 6
229910052623 talc Inorganic materials 0.000 description 6
241000700199 Cavia porcellus Species 0.000 description 5
229940122601 Esterase inhibitor Drugs 0.000 description 5
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical group CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 5
230000003182 bronchodilatating effect Effects 0.000 description 5
239000003054 catalyst Substances 0.000 description 5
239000002329 esterase inhibitor Substances 0.000 description 5
229960001340 histamine Drugs 0.000 description 5
239000003921 oil Substances 0.000 description 5
235000019198 oils Nutrition 0.000 description 5
229920001223 polyethylene glycol Polymers 0.000 description 5
229960002052 salbutamol Drugs 0.000 description 5
238000010998 test method Methods 0.000 description 5
210000003437 trachea Anatomy 0.000 description 5
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
229930006000 Sucrose Natural products 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
239000000443 aerosol Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
238000009835 boiling Methods 0.000 description 4
229910052794 bromium Inorganic materials 0.000 description 4
230000000052 comparative effect Effects 0.000 description 4
MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 4
229940079593 drug Drugs 0.000 description 4
238000001914 filtration Methods 0.000 description 4
229960005051 fluostigmine Drugs 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
230000007062 hydrolysis Effects 0.000 description 4
238000006460 hydrolysis reaction Methods 0.000 description 4
239000007788 liquid Substances 0.000 description 4
239000003208 petroleum Substances 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
150000003254 radicals Chemical class 0.000 description 4
230000009467 reduction Effects 0.000 description 4
238000010992 reflux Methods 0.000 description 4
239000007787 solid Substances 0.000 description 4
229960004793 sucrose Drugs 0.000 description 4
ZUYWFUUNQDJUKG-UHFFFAOYSA-N 1-(butylamino)ethanol Chemical group CCCCNC(C)O ZUYWFUUNQDJUKG-UHFFFAOYSA-N 0.000 description 3
HEQOJEGTZCTHCF-UHFFFAOYSA-N 2-amino-1-phenylethanone Chemical compound NCC(=O)C1=CC=CC=C1 HEQOJEGTZCTHCF-UHFFFAOYSA-N 0.000 description 3
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
244000025254 Cannabis sativa Species 0.000 description 3
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 3
208000033962 Fontaine progeroid syndrome Diseases 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000012876 carrier material Substances 0.000 description 3
229910052801 chlorine Inorganic materials 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 3
239000008298 dragée Substances 0.000 description 3
239000000975 dye Substances 0.000 description 3
239000003480 eluent Substances 0.000 description 3
238000002290 gas chromatography-mass spectrometry Methods 0.000 description 3
210000002837 heart atrium Anatomy 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 3
DLSOILHAKCBARI-UHFFFAOYSA-N n-benzyl-2-methylpropan-2-amine Chemical compound CC(C)(C)NCC1=CC=CC=C1 DLSOILHAKCBARI-UHFFFAOYSA-N 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
239000008213 purified water Substances 0.000 description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
235000010262 sodium metabisulphite Nutrition 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
229930182837 (R)-adrenaline Natural products 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
WQXWIKCZNIGMAP-UHFFFAOYSA-N 3',5'-Dihydroxyacetophenone Chemical compound CC(=O)C1=CC(O)=CC(O)=C1 WQXWIKCZNIGMAP-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
229920000945 Amylopectin Polymers 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
208000009079 Bronchial Spasm Diseases 0.000 description 2
208000014181 Bronchial disease Diseases 0.000 description 2
206010006482 Bronchospasm Diseases 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
206010038687 Respiratory distress Diseases 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
WKHOPHIMYDJVSA-UHFFFAOYSA-N [3-[2-(tert-butylamino)-1-hydroxyethyl]-5-(2-methylpropanoyloxy)phenyl] 2-methylpropanoate Chemical compound CC(C)C(=O)OC1=CC(OC(=O)C(C)C)=CC(C(O)CNC(C)(C)C)=C1 WKHOPHIMYDJVSA-UHFFFAOYSA-N 0.000 description 2
TVMXBDVCDVAXLP-UHFFFAOYSA-L [Na+].[Na+].[Na+].[O-]S(=O)S([O-])(=O)=O Chemical compound [Na+].[Na+].[Na+].[O-]S(=O)S([O-])(=O)=O TVMXBDVCDVAXLP-UHFFFAOYSA-L 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
FZGVEKPRDOIXJY-UHFFFAOYSA-N bitolterol Chemical compound C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)CNC(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 FZGVEKPRDOIXJY-UHFFFAOYSA-N 0.000 description 2
229960004620 bitolterol Drugs 0.000 description 2
230000007883 bronchodilation Effects 0.000 description 2
239000006172 buffering agent Substances 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
238000004440 column chromatography Methods 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
229960005139 epinephrine Drugs 0.000 description 2
235000013305 food Nutrition 0.000 description 2
238000013467 fragmentation Methods 0.000 description 2
238000006062 fragmentation reaction Methods 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
229950002451 ibuterol Drugs 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
229960001317 isoprenaline Drugs 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
239000000463 material Substances 0.000 description 2
125000002950 monocyclic group Chemical group 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
229960002657 orciprenaline Drugs 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
229920001592 potato starch Polymers 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 2
239000012453 solvate Substances 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
235000010356 sorbitol Nutrition 0.000 description 2
239000007921 spray Substances 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
238000003756 stirring Methods 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
210000001364 upper extremity Anatomy 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
239000001993 wax Substances 0.000 description 2
QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 1
MWOOKDULMBMMPN-UHFFFAOYSA-N 3-(2-ethyl-1,2-oxazol-2-ium-5-yl)benzenesulfonate Chemical compound O1[N+](CC)=CC=C1C1=CC=CC(S([O-])(=O)=O)=C1 MWOOKDULMBMMPN-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
YIIMEMSDCNDGTB-UHFFFAOYSA-N Dimethylcarbamoyl chloride Chemical compound CN(C)C(Cl)=O YIIMEMSDCNDGTB-UHFFFAOYSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical class OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
241000282412 Homo Species 0.000 description 1
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
102000006463 Talin Human genes 0.000 description 1
108010083809 Talin Proteins 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
CFUSMTBQBWPGOZ-UHFFFAOYSA-N Terbutaline-1-sulfate Chemical compound CC(C)(C)NCC(OS(O)(=O)=O)C1=CC(O)=CC(O)=C1 CFUSMTBQBWPGOZ-UHFFFAOYSA-N 0.000 description 1
DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
XXNWRMCMJABMLY-UHFFFAOYSA-N [1-(3,5-dihydroxyphenyl)-2-(propan-2-ylamino)ethyl] hydrogen sulfate Chemical compound S(=O)(=O)(O)OC(CNC(C)C)C1=CC(=CC(=C1)O)O XXNWRMCMJABMLY-UHFFFAOYSA-N 0.000 description 1
MHSCTPSUPCVLAG-UHFFFAOYSA-N [3-(2-bromoacetyl)-5-(ethylcarbamoyloxy)phenyl] n-ethylcarbamate Chemical compound CCNC(=O)OC1=CC(OC(=O)NCC)=CC(C(=O)CBr)=C1 MHSCTPSUPCVLAG-UHFFFAOYSA-N 0.000 description 1
PTZIWUJNBZOUQD-UHFFFAOYSA-N [3-(2-bromoacetyl)phenyl] n,n-dimethylcarbamate Chemical compound CN(C)C(=O)OC1=CC=CC(C(=O)CBr)=C1 PTZIWUJNBZOUQD-UHFFFAOYSA-N 0.000 description 1
CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
150000008065 acid anhydrides Chemical class 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
235000010385 ascorbyl palmitate Nutrition 0.000 description 1
CREXVNNSNOKDHW-UHFFFAOYSA-N azaniumylideneazanide Chemical group N[N] CREXVNNSNOKDHW-UHFFFAOYSA-N 0.000 description 1
KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
229940073608 benzyl chloride Drugs 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
239000000168 bronchodilator agent Substances 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
238000000262 chemical ionisation mass spectrometry Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229920001577 copolymer Chemical group 0.000 description 1
239000013078 crystal Substances 0.000 description 1
239000002178 crystalline material Substances 0.000 description 1
KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000006196 drop Substances 0.000 description 1
229940009662 edetate Drugs 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
229960002179 ephedrine Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
239000002031 ethanolic fraction Substances 0.000 description 1
WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 1
229960000645 histamine hydrochloride Drugs 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
229940041682 inhalant solution Drugs 0.000 description 1
230000003993 interaction Effects 0.000 description 1
239000013067 intermediate product Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
229940125386 long-acting bronchodilator Drugs 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
150000002740 methanolamines Chemical class 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
AMSQLGKJQMTZNO-UHFFFAOYSA-N n-benzyl-1-methylcyclobutan-1-amine Chemical compound C=1C=CC=CC=1CNC1(C)CCC1 AMSQLGKJQMTZNO-UHFFFAOYSA-N 0.000 description 1
MMNNFMKNCOKXLZ-UHFFFAOYSA-N n-benzyl-2-methylpropan-2-amine;hydrobromide Chemical compound Br.CC(C)(C)NCC1=CC=CC=C1 MMNNFMKNCOKXLZ-UHFFFAOYSA-N 0.000 description 1
KCAPTTPXCZRLTD-UHFFFAOYSA-N n-benzylcyclobutanamine Chemical compound C=1C=CC=CC=1CNC1CCC1 KCAPTTPXCZRLTD-UHFFFAOYSA-N 0.000 description 1
125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
150000002895 organic esters Chemical class 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical compound BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 1
229960001416 pilocarpine Drugs 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
239000013558 reference substance Substances 0.000 description 1
230000002040 relaxant effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
230000004617 sleep duration Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000035882 stress Effects 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
150000003460 sulfonic acids Chemical class 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
239000002966 varnish Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
- C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
- C07C215/34—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton and at least one hydroxy group bound to another carbon atom of the carbon skeleton
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Macromonomer-Based Addition Polymer (AREA)
Luminescent Compositions (AREA)
Separation Of Suspended Particles By Flocculating Agents (AREA)
Saccharide Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DD81231626A 1980-07-09 1981-07-09 Verfahren zur herstellung von aminoaethanolen DD202001A5 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB8022439		1980-07-09
GB8116441		1981-05-29

Publications (1)

Publication Number	Publication Date
DD202001A5 true DD202001A5 (de)	1983-08-24

Family

ID=26276161

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD81231626A DD202001A5 (de)	1980-07-09	1981-07-09	Verfahren zur herstellung von aminoaethanolen

Country Status (29)

Country	Link
US (2)	US4419364A (fr)
EP (1)	EP0043807B1 (fr)
KR (3)	KR850000301B1 (fr)
AT (1)	ATE7689T1 (fr)
AU (1)	AU539976B2 (fr)
CA (1)	CA1180021A (fr)
CS (1)	CS221845B2 (fr)
CY (1)	CY1273A (fr)
DD (1)	DD202001A5 (fr)
DE (1)	DE3163871D1 (fr)
DK (1)	DK157678C (fr)
ES (3)	ES503768A0 (fr)
FI (1)	FI73666C (fr)
GR (1)	GR74291B (fr)
HK (1)	HK5385A (fr)
HU (2)	HU187611B (fr)
IE (1)	IE51373B1 (fr)
IS (1)	IS1262B6 (fr)
LU (1)	LU88304I2 (fr)
MX (1)	MX9203239A (fr)
MY (1)	MY8700026A (fr)
NO (2)	NO152130C (fr)
NZ (1)	NZ197628A (fr)
PH (2)	PH16535A (fr)
PL (1)	PL128513B1 (fr)
PT (1)	PT73336B (fr)
SG (1)	SG79784G (fr)
SU (1)	SU1128830A3 (fr)
YU (3)	YU42116B (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE8904064D0 (sv) *	1989-12-01	1989-12-01	Astra Ab	Improved method of preparing an intermediate for the manufacture of bambuterol
SE9000948D0 (sv)	1990-03-16	1990-03-16	Draco Ab	New use
US5830422A (en) *	1995-06-23	1998-11-03	Ormiston Mining And Smelting Co. Ltd.	Method for production of sodium bicarbonate, sodium carbonate and ammonium sulfate from sodium sulfate
EP0892639A4 (fr) *	1996-01-29	1999-06-09	Savor Evelyn	PROCEDE DE TRAITEMENT DES CONTRACTIONS UTERINES INDESIRABLES PAR UTILISATION D'ISOMERES R OU RR OPTIQUEMENT PURS D'AGONISTES -g(b)-2 ADRENERGIQUES
SE9604752D0 (sv) *	1996-12-20	1996-12-20	Astra Ab	Formulation and use
KR20030085658A (ko) *	2002-04-30	2003-11-07	한올제약주식회사	밤부테롤의 개선된 합성방법
AU2002332488A1 (en) *	2002-08-08	2004-02-25	J. L. Cheng	R-bambuterol, its preparation and therapeutic uses
US7495028B2 (en) *	2002-08-08	2009-02-24	Wen Tan	R-bambuterol, its preparation and therapeutic uses
AR045536A1 (es) *	2003-08-29	2005-11-02	Ranbaxy Lab Ltd	Inhibidores de la fosfodiesterasa tipo -iv
US20070259874A1 (en) *	2003-11-26	2007-11-08	Palle Venkata P	Phosphodiesterase Inhibitors
WO2006081986A1 (fr) *	2005-02-07	2006-08-10	F.Hoffmann-La Roche Ag	Combinaison de bambuterol et d'inhibiteur d'integrine
US7915286B2 (en)	2005-09-16	2011-03-29	Ranbaxy Laboratories Limited	Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
EP1948167A1 (fr) *	2005-10-19	2008-07-30	Ranbaxy Laboratories, Ltd.	Compositions d'inhibiteurs de la phosphodiesterase de type iv
RU2008119323A (ru)	2005-10-19	2009-11-27	Рэнбакси Лабораториз Лимитед (In)	Фармацевтические композиции мускаринового рецептора
NZ574905A (en)	2006-08-22	2011-12-22	Ranbaxy Lab Ltd	Matrix metalloproteinase inhibitors
EP2066661A2 (fr) *	2006-09-22	2009-06-10	Ranbaxy Laboratories Limited	Inhibiteurs de phosphodiesterase
JP2010504323A (ja) *	2006-09-22	2010-02-12	ランバクシーラボラトリーズリミテッド	Ｉｖ型ホスホジエステラーゼの阻害物質
US20080207659A1 (en) *	2007-02-15	2008-08-28	Asit Kumar Chakraborti	Inhibitors of phosphodiesterase type 4
US20110130403A1 (en) *	2007-03-14	2011-06-02	Ranbaxy Laboratories Limited	Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
SI2124944T1 (sl) *	2007-03-14	2012-05-31	Ranbaxy Lab Ltd	Derivati pirazolo b piridina kot inhibitorji fosfodiesteraze
EP2111861A1 (fr)	2008-04-21	2009-10-28	Ranbaxy Laboratories Limited	Compositions d'inhibiteurs de type IV de la phosphodiestérase
WO2012014114A1 (fr)	2010-07-30	2012-02-02	Ranbaxy Laboratories Limited	Inhibiteurs de métalloprotéinase de matrice
SG188642A1 (en)	2010-09-24	2013-05-31	Ranbaxy Lab Ltd	Matrix metalloproteinase inhibitors
MY176727A (en)	2012-12-03	2020-08-20	Pfizer	Selective androgen receptor modulators
US9784726B2 (en)	2013-01-08	2017-10-10	Atrogi Ab	Screening method, a kit, a method of treatment and a compound for use in a method of treatment
CN104557614B (zh) *	2014-12-15	2017-01-04	广东东阳光药业有限公司	一种胺的还原方法
CN105622461B (zh) *	2016-01-29	2018-06-19	华南理工大学	一种化合物及其制备方法与应用
CN105859589B (zh) *	2016-04-05	2018-09-28	深圳市康立生生物科技有限公司	一种制备班布特罗杂质c的方法
GB201714740D0 (en)	2017-09-13	2017-10-25	Atrogi Ab	New compounds and uses
GB201714734D0 (en)	2017-09-13	2017-10-25	Atrogi Ab	New compounds and uses
GB201714745D0 (en)	2017-09-13	2017-10-25	Atrogi Ab	New compounds and uses
GB201714736D0 (en)	2017-09-13	2017-10-25	Atrogi Ab	New compounds and uses
CN109942462B (zh) *	2019-03-06	2022-01-14	宏冠生物药业有限公司	一种盐酸班布特罗的合成工艺
GB201903832D0 (en)	2019-03-20	2019-05-01	Atrogi Ab	New compounds and methods
GB202205895D0 (en)	2022-04-22	2022-06-08	Atrogi Ab	New medical uses
EP4651867A1 (fr)	2023-01-20	2025-11-26	Atrogi AB	Agonistes du récepteur bêta 2-adrénergique pour le traitement ou la prévention de l'atrophie musculaire
GB202302225D0 (en)	2023-02-16	2023-04-05	Atrogi Ab	New medical uses
GB202303229D0 (en)	2023-03-06	2023-04-19	Atrogi Ab	New medical uses
CN117586152A (zh) *	2023-11-23	2024-02-23	黑龙江乌苏里江制药有限公司	一种盐酸班布特罗的制备方法
GB202403169D0 (en)	2024-03-05	2024-04-17	Atrogi Ab	New medical uses
WO2025238248A1 (fr)	2024-05-17	2025-11-20	Atrogi Ab	UTILISATION D'AGONISTES DU RÉCEPTEUR β2-ADRÉNERGIQUE DANS LE TRAITEMENT DE L'ATROPHIE MUSCULAIRE
CN120585720A (zh) *	2025-06-12	2025-09-05	肇庆学院	一种双靶点药物的经鼻给药制剂及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE178032C1 (fr)		1961-01-01
DE1643488U (de)	1949-11-28	1952-09-11	G E Hilge Fa	Brutgeraet.
DK85789C (da)	1955-07-05	1958-06-30	Cilag Ag	Fremgangsmåde til fremstilling af d,1- eller 1-isopropyl-aminometyl-(3,4-dihydroksy-fenyl)-karbinol eller salte deraf.
DE1768167U (de)	1958-04-02	1958-06-04	Artur O Herrmann	Warngeraet bei strassenhindernissen.
DE1275069B (de)	1960-02-15	1968-08-14	Boehringer Sohn Ingelheim	1-(3', 5'-Dihydroxyphenyl)-1-hydroxy-2-isopropylaminoalkane und Verfahren zu ihrer Herstellung
NL282274A (fr)	1961-09-14
FR1324857A (fr) *	1962-06-14	1963-04-19	Chemie Linz Ag	Procédé pour la préparation de dérivés de la phényléthanolamine
GB1141606A (en)	1965-04-12	1969-01-29	Rech S Et D Applic Scient Et M	Improvements in alkyl ethers of substituted phenylaminoethanols
DE1543372A1 (de)	1966-10-18	1971-04-01	Boehringer Sohn Ingelheim	Verfahren zur Herstellung von o-substituierten 3,4-Dioxyphenylalkanolaminen
US3937838A (en) *	1966-10-19	1976-02-10	Aktiebolaget Draco	Orally active bronchospasmolytic compounds and their preparation
SE358633B (fr)	1966-10-19	1973-08-06	Draco Ab
SE335359B (fr)	1966-10-19	1971-05-24	Draco Ab
NO132866C (fr)	1966-10-19	1976-01-21	Draco Ab
FR6087M (fr)	1967-01-10	1968-06-04
SE369299B (fr)	1967-10-18	1974-08-19	Draco Ab
SE338324B (fr)	1967-12-19	1971-09-06	Haessle Ab
GB1298771A (en)	1969-04-01	1972-12-06	Sterling Drug Inc	Carboxylic esters of hydroxyphenylalkanolamines
AT294046B (de)	1969-07-08	1971-11-10	Chemie Linz Ag	Verfahren zur Herstellung des N,N'-Bis[2-(3',4'-dihydroxyphenyl)-2-hydroxyäthyl]-hexamethylendiamins, seiner optisch aktiven Formen und der Salze derselben
US3657319A (en) *	1970-05-05	1972-04-18	Smith Kline French Lab	Alpha-aminoalkyl-4-hydroxy-3-carboalkoxyaminobenzyl alcohols
NO126437B (fr)	1970-08-05	1973-02-05	Draco Ab
NL7112938A (fr)	1970-09-30	1972-04-05
CH550771A (de)	1970-10-30	1974-06-28	Hoffmann La Roche	Verfahren zur herstellung von phenaethylaminderivaten.
US3876679A (en)	1970-12-09	1975-04-08	Aldrich Chem Co Inc	Di-substituted phenethylcarbamic acid esters
NL7213759A (fr)	1971-10-19	1973-04-25
US4011258A (en)	1973-06-21	1977-03-08	Aktiebolaget Draco	Orally active bronchospasmolytic compounds
FI56673C (fi)	1974-03-29	1981-02-04	Huhtamaeki Yhthymae Oy	Nytt foerfarande foer framstaellning av alfa-tert-bytylaminometyl-4-hydroxy-m-xylen-alfa1 alfa3-diol
JPS556625B2 (fr)	1974-05-16	1980-02-18
US4063025A (en) *	1975-02-05	1977-12-13	Yamanouchi Pharmaceutical Co., Ltd.	4-Substituted amino-α-aminomethylbenzyl alcohol derivatives
SE7510988L (sv)	1975-10-01	1977-04-02	Draco Ab	Nya farmaceutiskt aktiva foreningar
DE2710997C3 (de) *	1977-03-14	1980-08-14	Dr. Karl Thomae Gmbh, 7950 Biberach	4-Alkoxy carbonylamino-phenyläthanolamine, deren Herstellung und deren Verwendung als Arzneimittel

1981
- 1981-06-30 AT AT81850117T patent/ATE7689T1/de active
- 1981-06-30 CY CY1273A patent/CY1273A/xx unknown
- 1981-06-30 EP EP81850117A patent/EP0043807B1/fr not_active Expired
- 1981-06-30 DE DE8181850117T patent/DE3163871D1/de not_active Expired
- 1981-07-01 US US06/279,672 patent/US4419364A/en not_active Expired - Lifetime
- 1981-07-07 AU AU72618/81A patent/AU539976B2/en not_active Expired
- 1981-07-07 NZ NZ197628A patent/NZ197628A/en unknown
- 1981-07-07 PH PH25872A patent/PH16535A/en unknown
- 1981-07-07 IE IE1522/81A patent/IE51373B1/en not_active IP Right Cessation
- 1981-07-07 NO NO812311A patent/NO152130C/no unknown
- 1981-07-08 CS CS815265A patent/CS221845B2/cs unknown
- 1981-07-08 ES ES503768A patent/ES503768A0/es active Granted
- 1981-07-08 HU HU813788A patent/HU187611B/hu unknown
- 1981-07-08 IS IS2657A patent/IS1262B6/is unknown
- 1981-07-08 HU HU811986A patent/HU184959B/hu unknown
- 1981-07-08 FI FI812158A patent/FI73666C/fi not_active IP Right Cessation
- 1981-07-08 PL PL1981232108A patent/PL128513B1/pl unknown
- 1981-07-08 CA CA000381360A patent/CA1180021A/fr not_active Expired
- 1981-07-08 PT PT73336A patent/PT73336B/pt unknown
- 1981-07-08 SU SU813308249A patent/SU1128830A3/ru active
- 1981-07-08 DK DK303481A patent/DK157678C/da active
- 1981-07-09 GR GR65453A patent/GR74291B/el unknown
- 1981-07-09 KR KR1019810002490A patent/KR850000301B1/ko not_active Expired
- 1981-07-09 YU YU1704/81A patent/YU42116B/xx unknown
- 1981-07-09 DD DD81231626A patent/DD202001A5/de unknown
1982
- 1982-06-15 ES ES513109A patent/ES8304534A1/es not_active Expired
- 1982-06-15 ES ES513108A patent/ES513108A0/es active Granted
- 1982-07-06 US US06/395,650 patent/US4451663A/en not_active Expired - Lifetime
- 1982-07-23 PH PH27617A patent/PH19447A/en unknown
1983
- 1983-04-15 YU YU864/83A patent/YU43169B/xx unknown
- 1983-04-15 YU YU863/83A patent/YU43168B/xx unknown
1984
- 1984-09-26 KR KR1019840005924A patent/KR850000870B1/ko not_active Expired
- 1984-09-26 KR KR1019840005925A patent/KR850000871B1/ko not_active Expired
- 1984-11-09 SG SG797/84A patent/SG79784G/en unknown
1985
- 1985-01-17 HK HK53/85A patent/HK5385A/en not_active IP Right Cessation
1987
- 1987-12-30 MY MY26/87A patent/MY8700026A/xx unknown
1992
- 1992-06-24 MX MX9203239A patent/MX9203239A/es unknown
1993
- 1993-06-16 LU LU88304C patent/LU88304I2/fr unknown
1996
- 1996-06-27 NO NO1996008C patent/NO1996008I1/no unknown

Also Published As

Publication number	Publication date
PT73336A (en)	1981-08-01
NO1996008I1 (no)	1996-06-27
HU187611B (en)	1986-02-28
IE811522L (en)	1982-01-09
US4451663A (en)	1984-05-29
NO812311L (no)	1982-01-11
ES8304072A1 (es)	1983-02-16
NO152130B (no)	1985-04-29
IS2657A7 (is)	1982-01-10
YU86383A (en)	1983-12-31
PH16535A (en)	1983-11-10
LU88304I2 (fr)	1994-05-04
SU1128830A3 (ru)	1984-12-07
ES513109A0 (es)	1983-03-01
EP0043807A2 (fr)	1982-01-13
CS221845B2 (en)	1983-04-29
PL232108A1 (fr)	1982-08-02
PL128513B1 (en)	1984-02-29
NO152130C (no)	1985-08-07
YU42116B (en)	1988-04-30
CY1273A (en)	1985-03-08
IE51373B1 (en)	1986-12-10
FI73666C (fi)	1987-11-09
KR850000301B1 (ko)	1985-03-18
AU539976B2 (en)	1984-10-25
ATE7689T1 (de)	1984-06-15
DK157678C (da)	1990-06-18
GR74291B (fr)	1984-06-21
CA1180021A (fr)	1984-12-27
MY8700026A (en)	1987-12-31
FI812158L (fi)	1982-01-10
YU43168B (en)	1989-04-30
NZ197628A (en)	1985-07-12
ES8300678A1 (es)	1982-11-01
ES503768A0 (es)	1982-11-01
PT73336B (en)	1983-09-01
HK5385A (en)	1985-01-25
EP0043807B1 (fr)	1984-05-30
AU7261881A (en)	1982-01-14
KR850000870B1 (ko)	1985-06-22
DE3163871D1 (en)	1984-07-05
PH19447A (en)	1986-04-18
MX9203239A (es)	1992-07-01
KR850002741A (ko)	1985-05-15
YU43169B (en)	1989-04-30
KR850000871B1 (ko)	1985-06-22
YU170481A (en)	1983-12-31
IS1262B6 (is)	1987-03-27
DK303481A (da)	1982-01-10
HU184959B (en)	1984-11-28
FI73666B (fi)	1987-07-31
ES513108A0 (es)	1983-02-16
ES8304534A1 (es)	1983-03-01
US4419364A (en)	1983-12-06
KR830006174A (ko)	1983-09-20
EP0043807A3 (en)	1982-09-22
SG79784G (en)	1985-04-26
YU86483A (en)	1983-12-31
DK157678B (da)	1990-02-05
KR850002740A (ko)	1985-05-15

Publication	Publication Date	Title
DD202001A5 (de)	1983-08-24	Verfahren zur herstellung von aminoaethanolen
DE2365896B2 (de)	1980-02-28	Derivate des 4-(4-Diphenylmethylenpiperidino)-butan-l-ons und diese enthaltende Arzneimittel
DE2305092C2 (fr)	1987-10-01
DD144763A5 (de)	1980-11-05	Verfahren zur herstellung von phenethanolaminen
DE2640972A1 (de)	1977-04-14	Aminoaethanolderivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
DE1940566C3 (de)	1978-12-07	1- (2-Nitrilophenoxy)-2-hydroxy-3äthylaminopropan, Verfahren zu dessen Herstellung und dieses enthaltende Arzneimittel
DE2727144A1 (de)	1977-12-29	Arzneimittel auf der grundlage von chinolinderivaten
DE2632118B2 (de)	1979-02-01	Apovincaminolester und Verfahren zu deren Herstellung und Arzneimittel
DD202002A5 (de)	1983-08-24	Verfahren zur herstellung von aminoaethanolderivaten
DE3650311T2 (de)	1995-10-12	Verwendung von Quinazolinen zur Herstellung eines Arzneimittels zur Behandlung und Vorbeugung von Arrhythmie.
DD142875A5 (de)	1980-07-16	Verfahren zur herstellung von 2-aminoaethanolderivaten
DD200404A5 (de)	1983-05-04	Verfahren zur herstellung eines synergistisch wirkenden mittels
DD144764A5 (de)	1980-11-05	Verfahren zur herstellung von r-n-(2-phenyl-2-hydroxyethyl)-3-phenylpropylaminen
DE2754148A1 (de)	1978-06-08	Substituierte aminoaethanole, verfahren zu ihrer herstellung und ihre verwendung als arzneistoffe
DE3012190A1 (de)	1980-10-02	Pharmazeutisches mittel auf der basis 1,3,5-substituierter biuret-verbindungen
AT392968B (de)	1991-07-25	Neue xanthinderivate
DE2933005C2 (de)	1983-01-13	1-(3-Acyloxyphenyl)-2-aminoethanole, deren Säureadditionssalze, diese enthaltende Arzneimittel, sowie Verfahren zu ihrer Herstellung
DE2227846A1 (de)	1973-01-04	Phenoxyessigsaeure-derivate und verfahren zu ihrer herstellung
CH643536A5 (de)	1984-06-15	Alkanolaminderivate.
AT368126B (de)	1982-09-10	Verfahren zur herstellung von neuen substituierten aethanolaminen, und deren salzen
DE3046017C2 (de)	1986-09-25	Indolizin-Derivate, Verfahren zu deren Herstellung und pharmazeutische Zusammensetzung
DE2437883C3 (de)	1977-03-10	N-Substltuierte Glycinester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
AT371101B (de)	1983-06-10	Verfahren zur herstellung neuer optisch aktiver phenethanolamine und der pharmazeutisch unbedenklichen salze hiervon
AT350526B (de)	1979-06-11	Verfahren zur herstellung von neuen 2-amino-1- phenylaethanolen -(1) und von deren salzen
DE1618042C (fr)	1973-02-08